Twin Tree Management
ACAD icon

Twin Tree Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Twin Tree Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-76,887
Closed -$1.42M – 1312
2024
Q1 		$1.42M Buy
+76,887
New +$1.9M ﹤0.01% 1026
2020
Q1 		– Sell
-1,173
Closed -$50K – 1324
2019
Q4 		$50K Buy
+1,173
New +$51K ﹤0.01% 1114
2019
Q2 		– Sell
-1,092
Closed -$29K – 1209
2019
Q1 		$29K Buy
+1,092
New +$25.5K ﹤0.01% 1138

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Twin Tree Management's ACAD Position: Q2 2024 in Review

Twin Tree Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 76,887 shares — an estimated $1.42M sold.

Twin Tree Management first reported a position in ACAD in Q1 2019 and held it in 3 quarters. The position peaked at $1.42M in Q1 2024. 264 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

  • Twin Tree Management reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Twin Tree Management sold 76,887 Acadia Pharmaceuticals shares in Q2 2024, an estimated $1.42M.
  • Twin Tree Management first reported a position in Acadia Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Twin Tree Management's Acadia Pharmaceuticals position peaked at $1.42M in Q1 2024.
  • 264 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on Twin Tree Management's 13F filing for Q2 2024, filed 13 Aug 2024.